Elan Gorshein, DO, JD, MPH

home / authors / elan-gorshein-do-jd-mph

Articles

Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 24th 2023

A Q&A session with the expert panel.

Unmet Needs in the Treatment of Multiple Myeloma

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 17th 2023

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 17th 2023

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 10th 2023

Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.

Application of Bispecific Therapy in Clinical Practice

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 10th 2023

Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.

Updated Results of the MonumenTAL-1 Study in R/R MM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 3rd 2023

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.

Available Treatment Options for Patients With R/R MM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 3rd 2023

Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.

Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 26th 2023

Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.

Treatment Approaches in Patients With Transplant-Ineligible NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 26th 2023

Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.